Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Neucel Specialty Cellulose was a Canadian manufacturer specializing in the production of high-purity dissolving wood pulp, a key raw material for the pharmaceutical and specialty chemical industries. Based in Port Alice, British Columbia, the company operated a sulfite pulp mill that produced high-alpha cellulose used to manufacture pharmaceutical excipients such as microcrystalline cellulose (MCC) and methylcellulose. These products are essential for drug formulation, serving as binders, fillers, and coating agents in tablet production. Despite its role as a critical supplier in the global specialty cellulose market, the company faced significant financial and operational challenges. Neucel entered receivership in 2019 and subsequently ceased all manufacturing operations, leading to the closure of its Port Alice facility.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Neucel Specialty Cellulose.